[68ga]ga-nns309
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2024 (NCT06562192)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Fibroblast activation protein alphaRadiopharmaceutical
FAP radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07261631 | Phase 1 | Nov 24, 2025 | Novartis |
| NCT07144085 | Phase 1 | Sep 30, 2025 | China Medical University |
| NCT06562192 | Phase 1 | Sep 30, 2024 | Novartis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 2 | 2 | 1 | 2024 |
| China Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1